- Home
- ONON vs MDGL Comparison
ONON vs MDGL Comparison
Compare ONON & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONON | MDGL |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.1B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ONON | MDGL |
|---|---|---|
| Price | $37.11 | $522.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | $60.15 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 4.7M | 289.6K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $19.58 | $58.39 |
| Revenue Next Year | $19.98 | $48.55 |
| P/E Ratio | $56.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.41 | $284.02 |
| 52 Week High | $54.72 | $615.00 |
Technical Indicators
Market Signals| Indicator | ONON | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 58.29 |
| Support Level | $35.08 | $498.59 |
| Resistance Level | $37.89 | $545.29 |
| Average True Range (ATR) | 1.60 | 21.12 |
| MACD | -0.20 | 3.80 |
| Stochastic Oscillator | 42.56 | 76.86 |
Price Performance
Historical ComparisonAbout ONON On Holding AG
Founded in Switzerland in 2010, sportswear firm On Holding generates 93% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.